Eisbach Bio

Eisbach Bio is a company that develops drugs to target molecular vulnerabilities arising in cancer genomes. Its technology identifies the engines that drive genome rearrangements in tumors, and its screening and cellular platforms generate inhibitors that allow the company to target the key vulnerability present in genetically-defined tumors.